{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:22Z","timestamp":1786119562846,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/mjt.0b013e3181ee7370","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T06:23:28Z","timestamp":1282199008000},"page":"e146-e151","source":"Crossref","is-referenced-by-count":0,"title":["Management of F\/P+\/\u2212 Hypereosinophilic Syndromes"],"prefix":"10.1097","volume":"19","author":[{"given":"Ankur","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekar","family":"Palaniswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveet","family":"Wig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":". The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"R2-13-20210202","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome.","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":". and The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":". Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":". Clinical and molecular features of FIP1L1-PDFGRA () chronic eosinophilic leukemias.","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":". Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":". Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":". Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":". Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":". FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":". A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":". Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","article-title":". The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.","volume":"106","author":"Stover","year":"2005","journal-title":"Blood"},{"key":"R15-13-20210202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":". PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome.","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"R17-13-20210202","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","article-title":"Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.","volume":"121","author":"Butterfield","year":"1994","journal-title":"Ann Intern Med"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood.V96.13.4285","article-title":". Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia.","volume":"96","author":"Schandene","year":"2000","journal-title":"Blood"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2005.02.006","article-title":"Anti-IL-5 and hypereosinophilic syndromes.","volume":"115","author":"Sutton","year":"2005","journal-title":"Clin Immunol"},{"key":"R20-13-20210202","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":". Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.","volume":"349","author":"Plotz","year":"2003","journal-title":"N Engl J Med"},{"key":"R21-13-20210202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/blood.V108.11.373.373","article-title":". Steroid-sparing effects of Anti-IL-5 monoclonal antibody (Mepolizumab) therapy in patients with HES: a multi-center, randomized, double-blind, placebo-controlled trial.","volume":"108","author":"Rothenberg","year":"2006","journal-title":"Blood"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0b013e3181ee7370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:35:34Z","timestamp":1786041334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201209000-00013"}},"subtitle":["Case Report and Treatment Review"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181ee7370","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}